GrayMatters for PTSD - GfP A NON-INVASIVE, ADAPTIVE DIGITAL THERAPEUTIC SOLUTION FOR POST-TRAUMATIC STRESS DISORDER AND OTHER MENTAL DISORDERS

Summary

Post-traumatic stress disorder (PTSD) is a severe mental disorder, annually affecting 3.2% of the population with global market-size estimated at €7.5B. Current treatments’ success is marginal, costly, with severe side-effects. GrayMatters is the first to introduce a non-invasive
digital-therapeutics device harnessing brain plasticity to help PTSD patients control abnormal brain-region activity. Our patented innovation uses machine-learning to convert EEG signal to an fMRI-like signal of the amygdala such that patients learn to self-control their amygdala activity
level using affordable EEG-Neurofeedback device. Initial clinical-trials on stress-resilience & PTSD patients showed significant positive clinical results. The founders have 25+ years experience in commercialization, healthcare & technology with several startups exits/IPOs. LOIs
includes top mental-institutes and world-renowned KOLs of PTSD psychiatry. GMH was recently chosen as 1 of 8 innovative companies by Nature magazine.

Resources

Show all and search (2)

Unfold all

Fold all

More information & hyperlinks

Web resources:	https://cordis.europa.eu/project/id/190165249
Start date:	01-09-2022
End date:	31-05-2025
Total budget - Public funding:	3 592 625,00 Euro - 2 500 000,00 Euro

Cordis data

Original description

Post-traumatic stress disorder (PTSD) is a severe mental disorder, annually affecting 3.2% of the population with global market-size estimated at 7.5B. Current treatments success is marginal, costly, with severe side-effects. GrayMatters is the first to introduce a non-invasive
digital-therapeutics device harnessing brain plasticity to help PTSD patients control abnormal brain-region activity. Our patented innovation uses machine-learning to convert EEG signal to an fMRI-like signal of the amygdala such that patients learn to self-control their amygdala activity
level using affordable EEG-Neurofeedback device. Initial clinical-trials on stress-resilience & PTSD patients showed significant positive clinical results. The founders have 25+ years experience in commercialization, healthcare & technology with several startups exits/IPOs. LOIs
includes top mental-institutes and world-renowned KOLs of PTSD psychiatry. GMH was recently chosen as 1 of 8 innovative companies by Nature magazine.